Explore

Why Teenagers Take More Risks Even When They Know the Consequences

Why Teenagers Take More Risks Even When They Know the Consequences

Decision-making is a skill that evolves significantly throughout an individual's lifespan, with distinct characteristics emerging during childhood,...

Genentech and Roche to Present New Alzheimer's Disease Data at CTAD 2026, Highlighting Multi-pronged Therapeutic and Diagnostic Approaches

Genentech and Roche to Present New Alzheimer's Disease Data at CTAD 2026, Highlighting Multi-pronged Therapeutic and Diagnostic Approaches

Genentech, a member of the Roche Group, announced it will present new data from its Alzheimer's disease portfolio at the 19th Clinical Trials on Alzheimer’s Disease (CTAD) Congress in Boston from November 16-19, 2026. The presentations will cover advancements in both pharmaceuticals and diagnostics, emphasizing a comprehensive strategy to address Alzheimer's. Key pharmaceutical updates include new Phase Ib/IIa Brainshuttle™ AD study data for trontinemab, demonstrating rapid amyloid removal, and the design specifics for the Phase III PrevenTRON study of trontinemab in preclinical Alzheimer's. Additionally, Genentech and Roche are initiating a new Phase II clinical trial, TARBELA-AD, to evaluate the investigational oral NLRP3 inhibitor RG6434, which targets neuroinflammation. On the diagnostic front, Roche will present global clinical and health economic data for its Elecsys® pTau217 and Elecsys pTau181 blood tests, supporting earlier and more accurate diagnosis of Alzheimer's disease. These efforts reflect ...

Acadia Pharmaceuticals to Present Remlifanserin Data at Alzheimer's Disease Conference

Acadia Pharmaceuticals to Present Remlifanserin Data at Alzheimer's Disease Conference

Acadia Pharmaceuticals Inc. announced it will present two data presentations related to Alzheimer's disease psychosis (ADP) and its investigational drug, remlifanserin, at the 2026 Clinical Trials on Alzheimer's Disease (CTAD) conference in Boston. The presentations will include findings from the Phase 2 portion of the ongoing RADIANT clinical trial program, which evaluates remlifanserin in patients with ADP. An oral presentation will detail the efficacy and safety of remlifanserin, while a poster presentation will examine biomarker heterogeneity among patients meeting clinical criteria for ADP. Remlifanserin is a novel, highly selective 5-HT2A receptor inverse agonist being developed to treat psychosis associated with Alzheimer's disease and Lewy body dementia. Currently, there is no FDA-approved drug specifically for the treatment of Alzheimer's disease psychosis.

Congresswoman Schrier Introduces Healthy Meal Time Act to Mandate Adequate Lunch and Recess for Students

Congresswoman Schrier Introduces Healthy Meal Time Act to Mandate Adequate Lunch and Recess for Students

Congresswoman Kim Schrier, M.D. (WA-08), a pediatrician and mother, has introduced the Healthy Meal Time Act, co-sponsored by Congresswoman Suzanne Bonamici (OR-01). This legislation aims to ensure that schools allocate sufficient time for children to consume nutritious meals and engage in recess activities daily. Currently, there are no federal guidelines dictating adequate school lunch times. The proposed Act would direct the U.S. Department of Agriculture, in collaboration with the U.S. Department of Education, to conduct a study. This study would identify and disseminate successful strategies and best practices for meal and recess timing among schools. The Centers for Disease Control and Prevention (CDC) recommends a minimum of 20 minutes of seated eating time for lunch, and this bill would incorporate such recommendations, alongside considerations for non-eating activities and the time required to eat minimally processed foods, into the best practices developed.

Dreem Health and Withings Partner to Integrate Sleep Tracking with Clinical Care

Dreem Health and Withings Partner to Integrate Sleep Tracking with Clinical Care

Dreem Health, a virtual sleep clinic, has partnered with wearables technology company Withings to bridge the gap between personal sleep tracking data and professional medical care. This collaboration allows users of Withings Sleep Mat and ScanWatch to securely share up to 14 nights of their recent sleep data with a licensed Dreem Health provider before their initial consultation. The integration aims to provide clinicians with objective data to inform clinical evaluations and develop personalized treatment plans for patients. This initiative addresses the issue that while sleep tracking is increasingly common, the data often does not reach healthcare professionals, leaving many conditions like sleep apnea undiagnosed. Dreem Health accepts most major insurance plans across all 50 states and offers a self-pay option.

Roche Initiates Phase II Clinical Trial for Alzheimer's Drug Targeting Neuroinflammation

Roche Initiates Phase II Clinical Trial for Alzheimer's Drug Targeting Neuroinflammation

Roche has announced the initiation of a new Phase II clinical trial, TARBELA-AD, to evaluate RG6434, an investigational oral NLRP3 inhibitor, for early symptomatic Alzheimer's disease. This study is part of Roche's broader strategy to address Alzheimer's by targeting various biological mechanisms, specifically focusing on neuroinflammation as a key driver of pathology in addition to amyloid aggregation. The announcement was made in anticipation of the 19th Clinical Trials on Alzheimer's Disease (CTAD) Congress in Boston, scheduled from November 16-19, 2026. According to Levi Garraway, M.D., Ph.D., Roche’s Chief Medical Officer, this trial aims to test additional therapeutic hypotheses to potentially halt or prevent disease progression, complementing their ongoing trontinemab programs. Roche's diagnostics division is also expanding access to earlier and more accurate Alzheimer's diagnosis through its blood-based biomarker portfolio, including the FDA-cleared Elecsys pTau217 and Elecsys pTau181 tests.

GE HealthCare to Establish MAGNUS Neuro Alliance for Advanced MRI Neuroscience Research

GE HealthCare to Establish MAGNUS Neuro Alliance for Advanced MRI Neuroscience Research

GE HealthCare has announced its intent to establish the MAGNUS Neuro Alliance, a collaborative research network focused on advancing neuroscience research using an ultra high-gradient head-only 3.0T MR system. This alliance will bring together researchers and clinicians from various fields, including neurology, radiology, psychiatry, and oncology, to explore how high-performance MR imaging can enable new scientific questions and research approaches in the study of the human brain. The group will also investigate the clinical translation of breakthrough MRI biomarkers. The MAGNUS system, designed to address limitations of conventional whole-body MR systems, will be used to investigate advanced anatomical, diffusion, and functional imaging research, allowing for the exploration of brain microstructure, microvasculature, and function. The alliance aims to accelerate discovery through multi-site clinical trials, joint research initiatives, and the exchange of protocols, data, and expertise.

American Academy of Pediatrics Updates Screen Time Guidance, Emphasizing Media Plans Over Strict Limits

American Academy of Pediatrics Updates Screen Time Guidance, Emphasizing Media Plans Over Strict Limits

American Academy of Pediatrics Updates Screen Time Guidance, Emphasizing Media Plans Over Strict Limits

Brain Health Research Shifts Focus to Nutrient Absorption and Personalized Nutrition

Brain Health Research Shifts Focus to Nutrient Absorption and Personalized Nutrition

The field of brain health research is evolving beyond simply identifying beneficial nutrients to understanding how these nutrients are absorbed, transported, and utilized by the brain. Scientists are now investigating the complex processes of nutrient delivery, such as how docosahexaenoic acid (DHA), a crucial omega-3 fatty acid, crosses the blood-brain barrier. A landmark study published in Nature identified a transporter called MFSD2A, which facilitates DHA movement into the brain when attached to lysophosphatidylcholine (LPC). This discovery highlights that the molecular form of a nutrient can significantly influence its brain accessibility. Additionally, there is a growing interest in personalized nutrition, recognizing that individual differences in age, health status, and metabolism may require tailored dietary recommendations rather than generalized approaches. This shift aims to provide a more detailed understanding of the relationship between nutrition and brain function.

Oral Appliances Emerge as Non-Surgical Alternative to CPAP for Obstructive Sleep Apnea

Oral Appliances Emerge as Non-Surgical Alternative to CPAP for Obstructive Sleep Apnea

Custom oral appliances are being presented as a comfortable and effective non-surgical alternative to Continuous Positive Airway Pressure (CPAP) therapy for individuals diagnosed with obstructive sleep apnea (OSA) or chronic snoring. These devices are custom-fit and designed to gently reposition the lower jaw during sleep, which helps to keep the airway open and improve breathing. The process involves advanced digital scanning and precise bite analysis to tailor the appliance specifically to the patient's anatomy, ensuring both comfort and effectiveness. Dental professionals often collaborate with sleep medicine specialists to provide coordinated and comprehensive care, aiming for better sleep, improved breathing, and enhanced overall health for patients. This approach offers a less intrusive option for those who find CPAP therapy challenging or uncomfortable.

Stable Housing Identified as Critical for Early Childhood Development and Health

Stable Housing Identified as Critical for Early Childhood Development and Health

A recent InBrief report highlights the crucial role of stable housing in supporting early childhood development and health. Stable housing provides a consistent environment that reduces family stress, facilitates regular sleep patterns and daily routines, and fosters social connections. Conversely, unstable housing can lead to significant disruptions, including changes in childcare and loss of access to community support. The report also points out that exposure to unsafe housing conditions, such as poor ventilation, mold, and pests, directly impacts the health and well-being of young children. This analysis draws from Working Paper 5, which examines how housing quality and stability affect children's developing brains and bodies, and how climate change exacerbates housing challenges.

Excessive Daytime Sleepiness Linked to Sleep Apnea and Other Conditions, Emphasizing Comprehensive Evaluation

Excessive Daytime Sleepiness Linked to Sleep Apnea and Other Conditions, Emphasizing Comprehensive Evaluation

Excessive daytime sleepiness (EDS), characterized by an uncontrollable urge to sleep or falling asleep at inappropriate times, is a significant health concern that can stem from various underlying medical conditions, with obstructive sleep apnea (OSA) being a common cause. In OSA, the upper airway repeatedly collapses during sleep, leading to micro-awakenings that fragment sleep and prevent restorative deep sleep. However, EDS can also be caused by other conditions such as narcolepsy, chronic insomnia, certain neurological diseases (e.g., Parkinson's, Alzheimer's), restless legs syndrome, and even side effects from medications. A comprehensive evaluation by a sleep medicine specialist, potentially including a sleep study (polysomnography), is crucial for accurate diagnosis and effective treatment.